THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry

Compare the 3-year outcomes of ranibizumab versus aflibercept in eyes with diabetic macular edema in daily practice. METHODS: This was a retrospective analysis of naive diabetic macular edema eyes starting intravitreal injections of ranibizumab (0.5 mg) or aflibercept (2 mg) from January 1, 2013 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabrielle, Pierre-Henry, Nguyen, Vuong, Creuzot-Garcher, Catherine, Arnold, Jennifer J., Mehta, Hemal, Duran, Mónica Asencio, Bougamha, Walid, Carreño, Ester, Viola, Francesco, Squirrell, David, Barthelmes, Daniel, Gillies, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2022
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112957/
https://www.ncbi.nlm.nih.gov/pubmed/35174799
http://dx.doi.org/10.1097/IAE.0000000000003428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112957/
https://www.ncbi.nlm.nih.gov/pubmed/35174799
http://dx.doi.org/10.1097/IAE.0000000000003428

Ejemplares similares